Finance

Lists
N1VS34:BVMF
Novartis AG Bdr
R$72,10
0,00%
(0,00) 1D
9 ຕ.ລ., 16 ໂມງ 56 ນາທີ 00 ວິນາທີ GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VS34...
Open
R$71,68
High
R$72,10
Low
R$71,68
Mkt. cap
292,13 ຕື້
Avg. vol.
200,00
Volume
64,00
52-wk high
R$87,30
52-wk low
R$65,03
Shares outstanding
2,03 ຕື້
No. of employees
75 ພັນ
Open
R$71,68
High
R$72,10
Low
R$71,68
Mkt. cap
292,13 ຕື້
Avg. vol.
200,00
Volume
64,00
52-wk high
R$87,30
52-wk low
R$65,03
Shares outstanding
2,03 ຕື້
No. of employees
75 ພັນ
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG Bdr
CEOVasant Narasimhan
Employees75,3 ພັນ
Founded7 ມ.ນ. 1996
Headquartersບາເຊວ, Basel City, ສະວິດເຊີແລນ
SectorPharmaceutical industry
Last report
21 ກ.ລ. 2026
Fiscal period
Q2 2026
US$2,41 / US$2,15
+12,21%beat
Revenue / Est. (USD)
14,95 ຕື້ / 14,06 ຕື້
+6,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
14,36 ຕື້
13,86 ຕື້
13,52 ຕື້
14,95 ຕື້
Cost of goods sold
3,54 ຕື້
3,54 ຕື້
3,44 ຕື້
3,68 ຕື້
Cost of revenue
3,54 ຕື້
3,54 ຕື້
3,44 ຕື້
3,68 ຕື້
Research and development expenses
2,86 ຕື້
2,84 ຕື້
2,78 ຕື້
2,74 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 ຕື້
3,44 ຕື້
3,14 ຕື້
3,23 ຕື້
Operating expense
6,24 ຕື້
6,46 ຕື້
5,96 ຕື້
6,10 ຕື້
Total operating expenses
9,77 ຕື້
10,00 ຕື້
9,40 ຕື້
9,78 ຕື້
Operating income
4,58 ຕື້
3,86 ຕື້
4,12 ຕື້
5,18 ຕື້
Other non operating income
-7,00 ລ້ານ
-130,00 ລ້ານ
4,00 ລ້ານ
19,00 ລ້ານ
EBT including unusual items
4,20 ຕື້
3,22 ຕື້
3,84 ຕື້
4,27 ຕື້
EBT excluding unusual items
4,29 ຕື້
3,49 ຕື້
3,78 ຕື້
4,73 ຕື້
Income tax expense
266,00 ລ້ານ
814,00 ລ້ານ
683,00 ລ້ານ
1,01 ຕື້
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 ລ້ານ
190,00 ລ້ານ
42,00 ລ້ານ
127,00 ລ້ານ
Net income
3,93 ຕື້
2,41 ຕື້
3,16 ຕື້
3,26 ຕື້
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 ລ້ານ
-
-
Interest expense
-281,00 ລ້ານ
-304,00 ລ້ານ
-343,00 ລ້ານ
-462,00 ລ້ານ
Net interest expenses
-281,00 ລ້ານ
69,00 ລ້ານ
-343,00 ລ້ານ
-462,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 ຕື້
4,96 ຕື້
5,24 ຕື້
6,30 ຕື້
Gain or loss from assets sale
81,00 ລ້ານ
80,00 ລ້ານ
-159,00 ລ້ານ
-247,00 ລ້ານ
AI content may include mistakes. Learn more
ແອັບຂອງ Google